125 related articles for article (PubMed ID: 17668540)
41. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis.
Ortonne JP; Lebwohl M; Em Griffiths C;
Eur J Dermatol; 2003; 13(2):117-23. PubMed ID: 12695125
[TBL] [Abstract][Full Text] [Related]
42. Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate.
van de Kerkhof P; Griffiths CE; Christophers E; Lebwohl M; Krueger GG
Dermatology; 2005; 211(3):256-63. PubMed ID: 16205071
[TBL] [Abstract][Full Text] [Related]
43. Alefacept for erosive lichen planus: a case series.
Chang AL; Badger J; Rehmus W; Kimball AB
J Drugs Dermatol; 2008 Apr; 7(4):379-83. PubMed ID: 18459520
[TBL] [Abstract][Full Text] [Related]
44. The effect of alefacept on T-cell subsets and cells expressing NK receptors in lesional psoriatic skin: the effects of monotherapy and combination treatment with calcipotriol.
Vissers WH; van Duijnhoven M; van Erp PE; de Jong EM; van de Kerkhof PC
J Dermatolog Treat; 2008; 19(6):344-50. PubMed ID: 19016104
[TBL] [Abstract][Full Text] [Related]
45. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study.
Mease PJ; Reich K;
J Am Acad Dermatol; 2009 Mar; 60(3):402-11. PubMed ID: 19028407
[TBL] [Abstract][Full Text] [Related]
46. Chronic plaque psoriasis.
Naldi L; Rzany B
Clin Evid; 2006 Jun; (15):2249-83. PubMed ID: 16973087
[No Abstract] [Full Text] [Related]
47. Alefacept for the treatment of psoriasis and other dermatologic diseases.
Strober BE; Menon K
Dermatol Ther; 2007; 20(4):270-6. PubMed ID: 17970892
[TBL] [Abstract][Full Text] [Related]
48. Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis.
Goedkoop AY; de Rie MA; Picavet DI; Kraan MC; Dinant HJ; van Kuijk AW; Tak PP; Bos JD; Teunissen MB
Arch Dermatol Res; 2004 Apr; 295(11):465-73. PubMed ID: 14968366
[TBL] [Abstract][Full Text] [Related]
49. Update on alefacept safety.
Wexler D; Searles G; Landells I; Shear NH; Bissonnette R; Papp K; Poulin Y; Langley R; Gulliver WP
J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S139-47. PubMed ID: 20053326
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic effects of a 12-week course of alefacept on nail psoriasis.
Körver JE; Langewouters AM; Van De Kerkhof PC; Pasch MC
J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1252-5. PubMed ID: 17062041
[TBL] [Abstract][Full Text] [Related]
51. Psoriasis responds to intralesional injections of alefacept and may predict systemic response to intramuscular alefacept: interim results of a single-arm, open-label study.
Gattu S; Busse K; Bhutani T; Chiang C; Nguyen T; Becker E; Koo JY
J Dermatolog Treat; 2012 Apr; 23(2):103-8. PubMed ID: 21254875
[TBL] [Abstract][Full Text] [Related]
52. Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis.
Krueger GG
Expert Opin Biol Ther; 2002 Apr; 2(4):431-41. PubMed ID: 11955280
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic hotline. Alefacept in the treatment of hyperkeratotic palmoplantar psoriasis.
Lior S; Grigory K; Pnina S; Joseph S; Felix P
Dermatol Ther; 2010; 23(5):556-60. PubMed ID: 20868412
[TBL] [Abstract][Full Text] [Related]
54. The effect of topical corticosteroids in combination with alefacept on circulating T-cell subsets in psoriasis.
Langewouters AM; Bovenschen HJ; De jong EM; Van Erp PE; Van De Kerkhof PC
J Dermatolog Treat; 2007; 18(5):279-85. PubMed ID: 17852631
[TBL] [Abstract][Full Text] [Related]
55. Alefacept in the treatment of psoriasis.
Sugiyama H; McCormick TS; Cooper KD; Korman NJ
Clin Dermatol; 2008; 26(5):503-8. PubMed ID: 18755368
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
[TBL] [Abstract][Full Text] [Related]
57. A randomized controlled trial of methotrexate and cyclosporine in the treatment of psoriasis.
Bigby M
Arch Dermatol; 2004 Mar; 140(3):347-8. PubMed ID: 15023778
[No Abstract] [Full Text] [Related]
58. Alefacept modifies long-term disease severity and improves the response to other treatments.
van Duijnhoven MW; de Jong EM; Gerritsen WJ; Pasch MC; van de Kerkhof PC
Eur J Dermatol; 2005; 15(5):366-73. PubMed ID: 16172047
[TBL] [Abstract][Full Text] [Related]
59. Alefacept: a safety profile.
Scheinfeld N
Expert Opin Drug Saf; 2005 Nov; 4(6):975-85. PubMed ID: 16255657
[TBL] [Abstract][Full Text] [Related]
60. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD
Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
